Moderna Cuts R&D Spending, Delays Profitability Target Amid Lowered Revenue Expectations
Moderna announces a 20% cut in research and development spending, aiming to stretch its cash reserves as vaccine sales...
Revolutionize Your Finance News Experience with MorningExpert!
🌟 Custom-Tailored News Just for You: Say goodbye to information overload. Our cutting-edge filtering technology curates your feed to perfection, delivering only the finance news that matches your interests and professional ambitions.
🔔 Flexible Updates, Your Way: How do you like your updates? Choose from instant app notifications, email digests, or captivating video summaries to stay informed on your own terms.
🎥 Engaging Video Summaries: Pressed for time? Let our expert anchors brief you with video summaries, giving you the essence of each news piece in minutes.
🚨 Personalized Alerts: Never miss out on what matters most. Set custom alarms for topics you’re passionate about, and be the first in the know.
📹 Create Your Own Video Content: Dive deeper into the topics that intrigue you with personalized videos. Generated on demand, these videos bring your chosen keywords or interests to life.
MorningExpert is more than a news app; it’s a dedicated companion for anyone passionate about finance. Whether you’re a seasoned professional, an avid enthusiast, or simply eager to stay updated with the finance world, our app ensures you’re always ahead of the curve.
With features designed to make staying informed effortless and enjoyable—such as custom alarms and on-demand video content—navigating the finance landscape has never been simpler or more tailored to your needs.
Transform the way you consume finance news. Download MorningExpert now and step into a world of precision-informed finance knowledge. Your next-level finance journey starts here!
acquisition adjusted earnings AI analysts apple artificial intelligence Bitcoin CEO China demand dividend Donald Trump Dow Jones Industrial Average earnings economy extreme event FactSet Federal Reserve fourth quarter growth guidance hamas inflation interest rates investment investors Israel Microsoft net income net profit Nvidia profit revenue revenue growth S&P 500 sales shareholders shares stock stock market stocks tesla third quarter Trump Wall Street
Moderna announces a 20% cut in research and development spending, aiming to stretch its cash reserves as vaccine sales...
Moderna Inc. announced progress towards new vaccine approvals but revealed plans to cut research-and-development spending by 20% and reduce...
Moderna's stock plunged Thursday after the company announced a major cut to its research and development efforts, aiming to...
The FDA has approved updated Covid-19 vaccines from Pfizer and Moderna for ages 6 months and up, targeting the...
Pfizer announced today that its RSV vaccine candidate, Abrysvo, generated strong neutralizing responses in a Phase 3 study after...
Moderna's stock plunged 21%, erasing its gains for the year, after the biotech company cut its sales guidance for...
In a groundbreaking development, Merck & Co. has announced positive results from a late-stage study of its proposed clesrovimab...
Moderna's stock rose 1.5% after an advisory panel to the European Union's medical regulator adopted a positive opinion on...
Pfizer, GSK, and Moderna stocks dropped after CDC advisers recommended narrowing the RSV vaccine eligibility to those aged 75...
Moderna's RSV vaccine, mResvia, showed only 50% efficacy after 18 months, lower than competitors GSK's Arexvy at 68% and...